A5051491632- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Mosquito-borne diseases and control
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Vectors
- Animal Virus Infections Studies
- Inflammasome and immune disorders
- Advanced biosensing and bioanalysis techniques
- Inhalation and Respiratory Drug Delivery
- Lipid Membrane Structure and Behavior
- Infection Control and Ventilation
- SARS-CoV-2 detection and testing
- Bacteriophages and microbial interactions
- Vaccine Coverage and Hesitancy
- Biosensors and Analytical Detection
- COVID-19 epidemiological studies
- COVID-19 impact on air quality
- Bacillus and Francisella bacterial research
- vaccines and immunoinformatics approaches
- Long-Term Effects of COVID-19
- Viral Infections and Outbreaks Research
Zhejiang Center for Disease Control and Prevention
2022-2024
To explore novel treatment/prevention of COVID-19, a broad-spectrum neutralizing antibody injection, anti- SARS-CoV-2 SA55 Injection (SA55 injection) was developed. Pharmacokinetics (PK) characteristics injection were evaluated in randomized, controlled, double-blind phase Ⅰ trial based on healthy participants aged 18-65 years. PK parameters (AUC0-∞, AUC0-t, and Cmax) assessed using one-way ANOVA the Power model. Results demonstrated that with Tmax 12.6 days half-life 103 days. In...
Background: A broad-spectrum anti-SARS-CoV-2 monoclonal antibody (mAb), SA55, is highly effective against SARS-CoV-2 variants. This trial aimed at demonstrating the safety, tolerability, local drug retention and neutralizing activity, systemic exposure level, immunogenicity of SA55 nasal spray in healthy individuals. Methods: phase I, dose-escalation clinical combined an open-label design with a randomized, controlled, double-blind design. Healthy participants aged 18–65 years were enrolled...
Abstract The recently mutated severe acute respiratory syndrome coronavirus 2 variant Omicron has very high infectivity and a strong ability to evolve evade immunity. We collected six sets of sera from uninfected individuals recovering breakthrough infections who completed homologous or heterologous booster immunization assessed their susceptibility against the BA.5.2.48, BF.7.14, XBB.1.5, XBB.1.5.4, XBB.1.16 subvariants. results demonstrated that variants possess an exceptional potential...
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have reduced susceptibility to neutralization by vaccines. In response the constantly updated variants, a global vaccine booster vaccination program has been launched. this study, we detected neutralizing antibody levels against wild-type (WT), Delta (B1.617.2), and Omicron BA.1 viruses in serum after each dose of CoronaVac vaccination. We found that significantly increased antibodies WT, Delta, BA.1. Compared...
SARS-CoV-2 has been evolving into a large number of variants, including the highly pathogenic Delta variant, and currently prevalent Omicron subvariants with extensive evasion capability, which raises an urgent need to develop new broad-spectrum neutralizing antibodies. Herein, we engineer two IgG-(scFv)
In 2009, severe fever with thrombocytopenia syndrome virus (SFTSV), also known as the
Background: Dengue virus (DENV) is the most widespread mosquito-borne virus, which can cause dengue fever with mild symptoms, or progress to fatal hemorrhagic and shock syndrome. As main target cells of DENV, macrophages are responsible for innate immune response against virus. Methods: In this study, we investigated role pyroptosis in pathogenic mechanism by examining level DENV-1-infected further screened differentially expressed microRNAs high-throughput sequencing predict that could...